鉴于近期市场波动较大，河南太龙药业股份有限公司与主承销协商确定取消本期科技创新债券的发行， 河南太龙药业股份有限公司将另择时机重新发行，并将按照《银行间债券市场非金融企业债务融资工具 发行注册规则》及《银行间债券市场非金融企业债务融资工具信息披露规则》的规定，做好河南太龙药 业股份有限公司科技创新债券的后续发行、兑付及信息披露工作。 截止收盘，太龙药业报收于6.43元/股。 根据公告，河南太龙药业股份有限公司于 2025 年 9 月 16 日、2025 年 9月 17 日在上海清算所网站、中 国货币网披露了河南太龙药业股份有限公司 2025 年度第一期科技创新债券相关发行公告文件，本期基 础发行金额 0 亿元，发行金额上限 4 亿元，发行日为 2025年 9 月 18 日、2025 年 9 月 19 日。 齐鲁晚报·齐鲁壹点 记者 刘相华 上海清算所9月22日发布《河南太龙药业股份有限公司2025 年度第一期科技创新债券取消发行公告》。 ...

证券代码：600222证券简称：太龙药业 公告编号：临2025-047 河南太龙药业股份有限公司关于接受间接控股股东担保并支付担保费暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 为提高河南太龙药业股份有限公司（以下简称"公司"）融资效率，公司间接控股股东郑州高新投资控 股集团有限公司（以下简称"高新投控"）拟为公司在金融机构的贷款提供最高时点金额不超过6.97亿元 （含）的连带责任保证，担保期限自本次董事会审议通过之日起至2028年3月30日止，担保费用总金额 预计不超过1,385.92万元。 ● 高新投控为公司间接控股股东，根据《上海证券交易所股票上市规则》第6.3.3条的规定，高新投控为 公司的关联法人，本次交易构成关联交易。 ● 本次关联交易不构成《上市公司重大资产重组管理办法》规定的重大资产重组。 ● 至本次关联交易为止，过去12个月内，公司及公司控股子公司与同一关联人发生的关联交易见公告正 文；公司及公司控股子公司未与其他关联方发生同类且未履行审议、披露义务的关联交易。 一、关 ...

Group 1: Changshan Pharmaceutical - The company is preparing for clinical trials of Aibennate peptide for weight loss, with no current plans for oral formulation development [1] - Aibennate peptide is a long-acting GLP-1 receptor agonist, developed through chemical modification of exenatide [1] - The marketing preparation includes team building, product knowledge training, and marketing strategy formulation [1] Group 2: Fosun Pharma - Four innovative drugs approved in the first half of the year are expected to gradually increase sales in the coming months [2] - Innovative drug revenue exceeded 4.3 billion yuan, a year-on-year increase of 14.26%, accounting for over 30% of total drug revenue [2] - The company is actively participating in negotiations for the inclusion of its innovative drugs in insurance and national basic medical insurance directories [2] Group 3: Tiantan Biological Products - The company has established an international cooperation department to enhance its global market presence [3] - Products such as tetanus immunoglobulin and rabies immunoglobulin have already been exported [3] - The company is focused on international certification and registration of key products [3] Group 4: Kangtuo Medical - The US-based subsidiary BIOPLATE has launched a local production line for PEEK plates [4] - The company has completed market access in nearly 40 countries and regions [4] - The marketing of "4D bioactive plates" and PEEK fixation systems is underway in the US [4] Group 5: Tailong Pharmaceutical - The company is focusing on the development of modified new drugs across various therapeutic areas including respiratory, digestive, and oncology [5] - Projects in progress include treatments for Alzheimer's disease and schizophrenia [5] Group 6: Heng Rui Pharmaceutical - The HRS-5635 injection has been included in the list of proposed breakthrough therapies [6][7] - Chronic hepatitis B infection affects approximately 257 million people globally, with a significant mortality rate [7] - There is a pressing need for more effective treatments to achieve functional cure for chronic hepatitis B [7]

证券代码：600222 证券简称：太龙药业 公告编号：临 2025-047 河南太龙药业股份有限公司 关于接受间接控股股东担保并支付担保费暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 为提高河南太龙药业股份有限公司（以下简称"公司"）融资 效率，公司间接控股股东郑州高新投资控股集团有限公司（以下简称 "高新投控"）拟为公司在金融机构的贷款提供最高时点金额不超过 6.97 亿元（含）的连带责任保证，担保期限自本次董事会审议通过 之日起至 2028 年 3 月 30 日止，担保费用总金额预计不超过 1,385.92 万元。 高新投控为公司间接控股股东，根据《上海证券交易所股票上 市规则》第 6.3.3 条的规定，高新投控为公司的关联法人，本次交易 构成关联交易。 本次关联交易不构成《上市公司重大资产重组管理办法》规定 的重大资产重组。 至本次关联交易为止，过去 12 个月内，公司及公司控股子公 司与同一关联人发生的关联交易见公告正文；公司及公司控股子公司 未与其他关联方发生同类且未履行审议、披露 ...

Core Insights - The company held a performance briefing for the first half of 2025 on September 17, where it addressed inquiries regarding the increase in gross margin for its traditional Chinese medicine (TCM) decoction pieces business [1] - Management highlighted that the fluctuation in medicinal herb prices was influenced by various external factors such as natural conditions, economic environment, and market supply-demand relationships [1] - The company reported a revenue of 762 million yuan for the first half of 2025, reflecting a year-on-year decline [1] Revenue and Financial Performance - The company achieved a revenue of 762 million yuan in the first half of 2025, which represents a year-on-year decrease [1] - Sales dispatches were affected due to the uneven progress of provincial drug standardization, despite the company's main products being selected in the national collection of traditional Chinese medicine [1] Product Development and Strategy - The company is focusing on self-initiated projects that are progressing rapidly, particularly in the development of modified new drugs with clear clinical value, high technical barriers, and good patient compliance [1] - The self-initiated projects cover various therapeutic areas including respiratory, digestive, infectious diseases, tumors, and mental health [1] Market Conditions - Management noted that the company is closely monitoring the prices of medicinal herbs due to the diverse range of herb varieties and specifications [1] - The company is leveraging the "Tongjun Hall Digital Center" to enhance the traceability system for medicinal materials [1]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 600222 | 太龙药业 | 6.55 | -1.36% | 16.19万 | 1.06亿 | | 600993 | 马应龙 | 27.03 | -1.35% | 6.63万 | 1.80亿 | | 300519 | 新光药业 | 16.65 | -1.30% | 3.76万 | 6293.56万 | | 002082 | 万邦德 | 9.70 | -1.22% | 18.51万 | 1.81亿 | | 301331 | 恩威医药 | 34.12 | -1.13% | 6669.52 | 2288.11万 | | 300534 | 陇神戎发 | 66'6 | -0.99% | 8.10万 | 8131.19万 | | 002737 | 癸化约业 | 15.64 | -0.95% | 4.90万 | 7674.99万 | | 600285 | 羚锐制药 | 22.95 | -0.86% | 6.17万 | 1.42亿 | | 000423 | 东阿 ...

Group 1 - Huida Sanitary Ware plans to publicly transfer 100% equity and debt of Guangxi Xingaosheng, with debt amounts of 132 million and 138 million yuan as of June 30, 2025 [1] - Sainuo Medical received administrative regulatory measures from Tianjin Securities Regulatory Bureau due to inaccurate information disclosure in quarterly reports [2][3] - Jiangling Motors reported August vehicle sales of 30,003 units, a year-on-year increase of 8.92% [6] Group 2 - Jimin Health's controlling shareholder plans to reduce its stake by up to 3%, totaling 15.75 million shares [7] - Satellite Chemical announced routine maintenance of polyethylene and ethylene glycol facilities, expected to last 45 days [8] - Hubei Yihua's 200,000-ton caustic soda project has been successfully put into production [10] Group 3 - Shanghai Pharmaceuticals' Dihydroxypropyl Theophylline Injection has passed the consistency evaluation for generic drugs [13] - Ningbo Construction's subsidiaries won construction projects worth 1.117 billion yuan [16] - Wens Foodstuff reported August sales revenue of 4.825 billion yuan from live pigs, with a year-on-year decrease in revenue and price [28] Group 4 - Long-term Logistics announced the resignation of its deputy general manager due to personal reasons [44] - Huaming Equipment proposed a cash dividend of 2 yuan per 10 shares, totaling 179 million yuan [46] - Transsion Holdings plans to distribute a cash dividend of 0.8 yuan per share [49]

Core Viewpoint - The company has received approval to register and issue a total of up to 800 million RMB in short-term financing bonds, which will be managed by two banks as joint lead underwriters [1][2]. Group 1 - The company held board meetings on July 1 and July 17, 2025, to approve the application for the issuance of short-term financing bonds [1]. - The registration amount for the short-term financing bonds is set at 800 million RMB, valid for two years from the date of the acceptance notice [1][2]. - The company plans to issue the bonds in phases during the registration validity period, depending on its funding needs and market conditions [2]. Group 2 - The company is required to disclose the issuance results through channels recognized by the trading association after the completion of the bond issuance [2]. - The issuance will comply with relevant laws, regulations, and self-regulatory management rules set by the trading association [2].

证券代码：600222 证券简称：太龙药业 公告编号：临 2025-046 河南太龙药业股份有限公司 关于超短期融资券获准注册的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 河南太龙药业股份有限公司（以下简称"公司"）分别于 2025 年 7 月 1 日、2025 年 7 月 17 日召开第九届董事会第三十二次会议和 2025 年第二次临时股东大会，审议通过了《关于拟申请注册发行超 短期融资券的议案》，同意公司向中国银行间市场交易商协会（以下 简称"交易商协会"）申请注册发行总额不超过（含）人民币 8 亿元 的超短期融资券。具体内容详见公司于 2025 年 7 月 2 日、2025 年 7 月 18 日在上海证券交易所网站（www.sse.com.cn）披露的相关公告。 近日，公司收到中国银行间市场交易商协会出具的《接受注册通 知书》（中市协注﹝2025﹞SCP239 号），交易商协会决定接受公司 科技创新债券注册，主要内容如下： 二、公司在注册有效期内可分期发行，接受注册后如需备案发行， 应事前先向交易商协会备案。公 ...

Core Viewpoint - Tailong Pharmaceutical (600222.SH) has received a registration notice from the China Interbank Market Dealers Association for its technology innovation bonds, indicating a strategic move to raise funds through short-term financing [1] Group 1: Registration Details - The company has registered for a super short-term financing bond with a total amount of 800 million yuan [1] - The registration is valid for two years from the date of the notice and is underwritten by China Minsheng Banking Corp and Shanghai Pudong Development Bank [1] - The company can issue the bonds in installments during the registration period and must file with the association prior to any issuance [1]